Inspire Investing LLC Sells 8,888 Shares of IQVIA Holdings Inc. $IQV

Inspire Investing LLC lowered its position in IQVIA Holdings Inc. (NYSE:IQV) by 23.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 29,817 shares of the medical research company’s stock after selling 8,888 shares during the quarter. Inspire Investing LLC’s holdings in IQVIA were worth $8,016,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Yousif Capital Management LLC raised its position in IQVIA by 1.9% during the 3rd quarter. Yousif Capital Management LLC now owns 19,608 shares of the medical research company’s stock valued at $5,272,000 after purchasing an additional 373 shares in the last quarter. MBL Wealth LLC purchased a new stake in shares of IQVIA in the 3rd quarter worth $348,000. NBT Bank N.A. bought a new position in shares of IQVIA during the 3rd quarter worth $602,000. Root Financial Partners LLC bought a new position in shares of IQVIA during the 3rd quarter worth $156,000. Finally, Arvest Investments Inc. grew its position in shares of IQVIA by 3.4% during the 3rd quarter. Arvest Investments Inc. now owns 6,747 shares of the medical research company’s stock worth $1,814,000 after buying an additional 220 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Weiss Ratings upgraded shares of IQVIA from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, September 24th. Deutsche Bank Aktiengesellschaft dropped their price objective on shares of IQVIA from $191.00 to $179.00 in a research note on Thursday, October 15th. Truist Financial reissued a “buy” rating and set a $329.00 price objective (up from $300.00) on shares of IQVIA in a report on Monday, September 28th. Mizuho boosted their price objective on shares of IQVIA from $275.00 to $300.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 7th. Finally, UBS Group started coverage on IQVIA in a report on Wednesday, September 30th. They set a “buy” rating and a $345.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $278.75.

IQVIA Stock Performance

IQV stock opened at $279.47 on Friday. The firm has a market cap of $46.00 billion, a price-to-earnings ratio of 34.67, a PEG ratio of 2.45 and a beta of 1.17. The firm has a 50-day simple moving average of $263.98 and a two-hundred day simple moving average of $216.43. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $282.98. The company has a debt-to-equity ratio of 2.18, a quick ratio of 0.71 and a current ratio of 0.71.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. During the same quarter in the previous year, the firm earned $2.81 EPS. The company’s quarterly revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts forecast that IQVIA Holdings Inc. will post 11.54 EPS for the current fiscal year.

Insider Activity at IQVIA

In other IQVIA news, insider Keriann Cherofsky sold 558 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total transaction of $136,827.18. Following the transaction, the insider owned 2,989 shares in the company, valued at approximately $732,932.69. This represents a 15.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider James G. Berkshire sold 2,668 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total transaction of $697,228.44. Following the completion of the transaction, the insider directly owned 10,890 shares of the company’s stock, valued at approximately $2,845,883.70. This represents a 19.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 15,581 shares of company stock worth $3,796,021 in the last 90 days. 1.70% of the stock is owned by insiders.

IQVIA Company Profile

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.